Reports and insights

Pathways to Value: Pharma in a Changing World analyses key trends that are reshaping how payers, patients and providers think about the value that medicines provide. It draws on research from three regions (Europe, emerging markets and US) to conclude with recommendations on new approaches to drug research, licensing and pricing.

Pharma’s New Productivity Challenge: Cost and Choice in the US Market looks at changes in the world’s largest pharmaceutical market and explores how the pharmaceutical sector will need to adapt to changing expectations and requirements from payers, providers and patients. This is the third of three regional reports in PharmaFutures 5.

Pharma’s New Productivity Challenge: Perspectives from Emerging Markets explores trends in health systems reform, and the changing role of pharmaceuticals in these growth markets. This is the second of three regional reports in PharmaFutures 5.

Pharma’s New Productivity Challenge: Perspectives from Europe explores the long-term pressures facing European health systems, the impacts of austerity on health systems, and their implications for pharmaceuticals in Europe. This is the first of three regional reports in PharmaFutures 5.

Shared Value (2011) explores the growing challenge of reconciling unmet patient need with pharmaceutical R&D, in the context of changes in what society is willing to pay for and concerns among investors about the return on investment. This is the final report of PharmaFutures 4.

Emerging Opportunities (2009) explores the link between sustainable pharmaceutical business models and global health outcomes in emerging markets. This is the final report of PharmaFutures 3.

Prescription for Long-Term Value (2007) outlines the findings of a 12 month facilitated dialogue between leading industry executives and major institutional investors on how the sector can better deliver long-term value to shareholders and consumers. This is the final report of PharmaFutures 2.

A Long-Term Value Outlook (2004) presents the findings of the PharmaFutures scenario planning project. The report is sponsored by three major pension funds – ABP (Netherlands), the Ohio Public Employees Retirement System (OPERS, US), and the Universities’ Superannuation Scheme (USS, UK). This is the final report of PharmaFutures 1.

Comments

Sophia Tickell

This is such a vital industry, with a strong and complex social contract. Hopefully, PharmaFutures can contribute to improved communications and a better alignment between society and shareholder needs.

Sophia Tickell, Director of PharmaFutures